Followers | 260 |
Posts | 19732 |
Boards Moderated | 0 |
Alias Born | 10/03/2004 |
Saturday, April 02, 2011 5:57:11 PM
This statement alone is so lacking in credibility, factuality, and authority that it renders every other statement... Well, you get the picture.
HIV replication material shifts, recombines and mutates so that any treatment is only effective for so long. Every treatment. Here are three sources on the topic:
Mechanistic Features of Recombination in HIV
Román Galetto and Matteo Negroni |Full Article in PDF|
Unité de Régulation Enzymatique des Activités Cellulaires. CNRS-URA 2185. Institut Pasteur. Paris, France
aidsreviews.com/resumen.asp?id=841&indice=200572&u=unp
Recombination favors the evolution of drug resistance in
HIV-1 during antiretroviral therapy
http://darwin.uvigo.es/download/papers/56.recModelHIV07.pdf
Accurately Measuring Recombination between Closely Related HIV-1 Genomes
http://www.ploscompbiol.org/article/info:doi%2F10.1371%2Fjournal.pcbi.1000766
Second, to use your own words, every drug has side effects, and all current HIV drugs have side effects and toxicity that must be closely monitored even at therapeutic levels. Yes, Atripla is well-tolerated in the clinical sense when compared to other HIV drugs, but that is only when compared to the alternative of not taking any drugs. Some more sources:
Atripla: http://www.hivandhepatitis.com/hiv_and_aids/atripla1.html#adv
"No, drug resistance is not inevitable. The best evidence that you could go for many years on this same regimen without resistance, provided you maintain excellent adherence, is to be found in long term clinical trials of this regimen. After 5 years in one extended study of this regimen, more than two thirds of people who started on this regimen were still well controlled. If you are able to maintain excellent adherence, you could well have full suppression after 5 or more years on this regimen." --Renslow Sherer, MD, University of Chicago
http://www.thebody.com/Forums/AIDS/Resistance/Q189790.html
The good doctor is putting a happy face on the inverse; 1/3rd of all patients in the 5 year study developed Atripla resistant HIV. There is already a need for a drug to replace Atripla for those 1/3rd of all patients who develop resistance.
Viruses are not made in the Amazon or Jungles of Southeast Asia:
Recent NNVC News
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/27/2024 08:15:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/09/2024 08:30:39 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 08/09/2024 08:05:25 PM
- NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • InvestorsHub NewsWire • 05/02/2024 02:07:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:53:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:55:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:44:48 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/04/2023 09:08:49 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 10/13/2023 08:30:41 PM
Lingerie Fighting Championships Signs Broadcast Deal With Maybacks Global Entertainment • BOTY • Sep 26, 2024 9:00 AM
Maybacks Global Entertainment and Lingerie Fighting Championships Enter Into Broadcast And Revenue Sharing Agreement • AHRO • Sep 26, 2024 8:30 AM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM